Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with long-term infliximab therapy

Journal of Rheumatology

Volumn 33, Issue 1, 2006, Pages 24-30

  Comby, Elisabeth ^a,b,d   Tanaff, Pascale ^a,c   Mariotte, Delphine ^a,b   Costentin Pignol, Valerie ^a,c   Marcelli, Christian ^a,c   Ballet, Jean Jacques ^a,c  

^a UNIVERSITÉ DE CAEN   (France)

^b Hospitalo Universitaire   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d CHU Clemenceau   (France)

Author keywords

Anti DNA antibodies; Antinuclear antibodies; Infliximab; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; C REACTIVE PROTEIN; CORTICOSTEROID; DNA ANTIBODY; DOUBLE STRANDED DNA; ETANERCEPT; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SINGLE STRANDED DNA; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANAPHYLAXIS; ANTIBODY DETECTION; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE DURATION; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE; HUMAN; IMMUNOTHERAPY; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DNA, SINGLE-STRANDED; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 30144431663     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Elliot MJ, Maini RN, Feldman NM, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36:1681-90.
2. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomised controlled trial. Ann Intern Med 1999;130:478-86.
3. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 2003;48:35-45.
4. Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet 2002;359:540-1.
5. Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: Cases series. J Rheumatol 2003;30:2287-91.
6. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
7. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open label and randomised placebo controlled trial. Arthritis Rheum 2000;43:2383-90.
8. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002;11:753-5.
9. Ali Y, Shah S. Infliximab-induced systemic lupus erythematosus. Ann Intern Med 2002;137:625-6.
10. De Bandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-alpha induced systemic lupus syndrome. Clin Rheumatol 2003;22:56-61.
11. Vermeire S, Noman M, Van Assche O, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003;125:32-9.
12. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 2003;9:176-8.
13. Shakoor N, Michalska M, Harris AC, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80.
14. Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002;61:1031-2.
15. Carlson E, Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum 2003;48:1165-6.
16. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MH. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003;28:604-7.
17. Lepore L, Marchetti F, Facchini S, Leone V, Ventura A. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol 2003;21:276-7.
18. Baeten D, Kruithof E, van den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34.
19. De Rycke L, Kruithof E, Van Damme N, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003;48:1015-23.
20. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
22. Tan EM. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 1982;33:167-240.
23. Preud'homme JL, Dation F, Rochard E, et al. Detection of anti-double stranded DNA antibodies of IgG, IgA and IgM classes by ELISA. Comparison with the Farr assay and indirect immunofluorescence. Presse Med 1988;17:1401-4.
24. Hylkema MN, Huygen H, Kramers C, et al. Clinical evaluation of a modified ELISA, using photobiotinylated DNA, for the detection of anti-DNA antibodies. J Immunol Methods 1994;170:93-102.
25. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997;40:1601-11.
26. Garcia-Planella E, Domenech E, Esteve-Comas M, et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's diseases treated with chimeric monoclonal anti-TNF-alpha antibodies (infliximab). Eur J Gastroenterol Hepatol 2003;15:351-4.
27. Louis M, Rauch J, Armstrong M, Fitzcharles MA. Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 2003;30:2557-62.
28. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomised, controlled trial. Ann Intern Med 1999;130:478-86.
29. Maini R, Breedveld F, Kalden J, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
30. Amoura Z, Koutouzov S, Piette JC. The role of nucleosomes in lupus. Curr Opin Rheumatol 2000;12:369-73.
31. Godinho F, Godfrin B, El Mahou S, Navaux F, Zabraniecki L, Cantagrel A. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol 2004;22:328-30.
32. Panush RS, Edwards L, Longley S, Webster E. "Rhupus" syndrome. Arch Intern Med 1988;148:1633-6.
33. Cohen MG, Webb J. Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases. Ann Rheum Dis 1987;46:853-8.
34. Jacob CO, McDevitt HO. Tumor necrosis factor-alpha in murine autoimmune "nephritis." Nature 1988;331:356-8.
35. Mitamura K, Kang H, Tomita Y, Hashimoto H, Sawada S, Horie T. Impaired tumor necrosis factor-alpha (TNF-alpha) production and abnormal B cell response to TNF-alpha in patients with systemic lupus erythematosus. Clin Exp Immunol 1991;85:386-91.
36. Aderka D, Wysenbeek A, Engelmann H, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111-20.
37. Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997;24:303-8.
38. Van den Brande JM, Braat H, Van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.
39. Pisetsky DS. Anti-DNA and autoantibodies. Curr Opin Rheumatol 2000;12:364-8.
40. Watts RA. Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol 2000;12:49-52.